Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

The short list of conventional therapeutic measures, including transfusions, iron chelation therapy, and hydroxyurea, expanded in 2023 to include luspatercept, which has been approved in Europe for ...